Dec. 17, 2009 -- Sepracor Inc. today announced that the United States Patent and Trademark Office has determined that U.S. Patent No. 6,444,673, which is a composition of matter patent that covers the human drug product LUNESTA® (eszopiclone), received patent term extension under 35 U.S.C. § 156.
The details can be read here.
No comments:
Post a Comment